StreetInsider.com News Articles

RBC Capital Upgrades Sartorius Stedim Biotech (DIM:FP) (SDMHF) to Outperform

Fri, 06 Mar 2026 01:11:50 +0000

RBC Capital analyst Charles Weston upgraded Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) from Sector Perform to Outperform with a price target of EUR210.00 (from EUR240.00).

The analyst comments: "We downgraded recommendations on Sartorius AG (SAG) and Sartorius Stedim (SSB) at the start of the year on the basis of a more cautious hiring trend across the bioprocessing industry, and both stocks' outperformance vs peers through H2 2025. Valuation appears to have now corrected for Stedim in particular, down 20% vs the market and c.10% vs larger peers TMO and DHR. Acknowledging that trading dynamics between SAG and SSB can be peculiar,

RBC Capital Upgrades Sartorius Stedim Biotech (DIM:FP) (SDMHF) to Outperform

Fri, 06 Mar 2026 01:11:50 +0000

RBC Capital analyst Charles Weston upgraded Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) from Sector Perform to Outperform with a price target of EUR210.00 (from EUR240.00).

RBC Capital Upgrades Sartorius Stedim Biotech (DIM:FP) (SDMHF) to Outperform

Fri, 06 Mar 2026 01:11:50 +0000

RBC Capital analyst Charles Weston upgraded Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) from Sector Perform to Outperform with a price target of EUR210.00 (from EUR240.00).

RBC Capital Upgrades Sartorius Stedim Biotech (DIM:FP) (SDMHF) to Outperform

Fri, 06 Mar 2026 01:11:50 +0000

RBC Capital analyst Charles Weston upgraded Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) from Sector Perform to Outperform with a price target of EUR210.00 (from EUR240.00).

RBC Capital Upgrades Sartorius Stedim Biotech (DIM:FP) (SDMHF) to Outperform

Fri, 06 Mar 2026 01:11:50 +0000

RBC Capital analyst Charles Weston upgraded Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) from Sector Perform to Outperform with a price target of EUR210.00 (from EUR240.00).

RBC Capital Upgrades Sartorius Stedim Biotech (DIM:FP) (SDMHF) to Outperform

Fri, 06 Mar 2026 01:11:50 +0000

RBC Capital analyst Charles Weston upgraded Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) from Sector Perform to Outperform with a price target of EUR210.00 (from EUR240.00).

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR233 at HSBC

Wed, 11 Feb 2026 07:41:17 +0000

HSBC analyst Shubhangi Gupta lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR233.00 (from EUR255.00) while maintaining a Buy rating.

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR233 at HSBC

Wed, 11 Feb 2026 07:41:17 +0000

HSBC analyst Shubhangi Gupta lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR233.00 (from EUR255.00) while maintaining a Buy rating.

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR233 at HSBC

Wed, 11 Feb 2026 07:41:17 +0000

HSBC analyst Shubhangi Gupta lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR233.00 (from EUR255.00) while maintaining a Buy rating.

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR233 at HSBC

Wed, 11 Feb 2026 07:41:17 +0000

HSBC analyst Shubhangi Gupta lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR233.00 (from EUR255.00) while maintaining a Buy rating.

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Raised to EUR256 at Jefferies

Wed, 04 Feb 2026 08:39:45 +0000

Jefferies analyst James Vane-Tempest raised the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR256.00 (from EUR236.00) while maintaining a Buy rating.

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Raised to EUR256 at Jefferies

Wed, 04 Feb 2026 08:39:45 +0000

Jefferies analyst James Vane-Tempest raised the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR256.00 (from EUR236.00) while maintaining a Buy rating.

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Raised to EUR256 at Jefferies

Wed, 04 Feb 2026 08:39:45 +0000

Jefferies analyst James Vane-Tempest raised the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR256.00 (from EUR236.00) while maintaining a Buy rating.

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Raised to EUR256 at Jefferies

Wed, 04 Feb 2026 08:39:45 +0000

Jefferies analyst James Vane-Tempest raised the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR256.00 (from EUR236.00) while maintaining a Buy rating.

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR230 at Barclays

Wed, 04 Feb 2026 04:06:09 +0000

Barclays analyst Charles Pitman lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR230.00 (from EUR250.00) while maintaining a Overweight rating.

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR230 at Barclays

Wed, 04 Feb 2026 04:06:09 +0000

Barclays analyst Charles Pitman lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR230.00 (from EUR250.00) while maintaining a Overweight rating.

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR230 at Barclays

Wed, 04 Feb 2026 04:06:09 +0000

Barclays analyst Charles Pitman lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR230.00 (from EUR250.00) while maintaining a Overweight rating.

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR230 at Barclays

Wed, 04 Feb 2026 04:06:09 +0000

Barclays analyst Charles Pitman lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR230.00 (from EUR250.00) while maintaining a Overweight rating.

Bernstein on EU Medtech: 'A Buying Opportunity or Is It Simply a Value Trap?'

Tue, 13 Jan 2026 07:32:02 +0000

Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.

The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.